<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680407</url>
  </required_header>
  <id_info>
    <org_study_id>U01AT003566-02</org_study_id>
    <secondary_id>IND 105,461 (orig. IND 74,887)</secondary_id>
    <nct_id>NCT00680407</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis</brief_title>
  <acronym>SyNCH</acronym>
  <official_title>A Multicenter, Randomized, Placebo Controlled Study to Assess the Safety and Efficacy of Orally Administered Silymarin Preparation (Legalon®) for the Treatment of Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Madaus Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Madaus Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Silymarin, also known as milk thistle, is an alternative medicine commonly found in health
      food and vitamin stores. People with liver disease sometimes use silymarin because it is
      thought to have liver protecting effects; however, this benefit has not been proven. The
      purpose of this research study is to determine the effectiveness of silymarin and assess the
      safety of different silymarin doses in patients with varying severity of liver disease
      compared to a placebo (lactose pill).

      Following a screening visit, patients with histologically confirmed NASH will be randomized
      to either placebo or one of two active treatment groups of silymarin (Legalon®). One active
      treatment group will receive 420 mg, each dose given three times daily, the other active
      treatment group will receive 700 mg, each dose given three times daily. Patients will be
      treated for 48-50 weeks. Participation in this research study requires the patient to travel
      to the clinic for at least 11 visits so recruitment will be limited to a geographically
      restricted area around participating clinical centers. Liver biopsy must be performed up to
      12 months prior to, and immediately after, the treatment phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double masked, placebo controlled Phase II trial to
      evaluate the safety and explore the efficacy of silymarin (Legalon®) compared with placebo on
      hepatic histology in patients with NASH (nonalcoholic steatohepatitis) after 48-50 weeks of
      therapy. This study was originally sponsored through a cooperative agreement (U01) award from
      the NCCAM and the NIDDK (RFA-AT-05-006: &quot;Phase I/II Trials of Silymarin for Chronic Liver
      Diseases&quot;), and now will continue with Madaus Inc. (Rottapharm Group) providing financial and
      regulatory support to the investigators. The broad aim of this study is to evaluate the
      safety and explore the efficacy of silymarin (Legalon®) in NASH patients and to form the
      basis for future studies which will establish its efficacy for treating patients with NASH.
      The specific objectives of this study are to determine the effect of silymarin (Legalon®) on
      the histologic NASH Activity Score (NAS), the liver enzymes, and HOMAr. The primary endpoint
      of the study is an improvement in the NAS by at least 2 points. Various secondary endpoints
      will be assessed, including the change in liver enzymes and HOMAr.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy - Improvement by at Least 2 Points in Histology (NAS)</measure>
    <time_frame>48-50 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - Occurrence of a Dose-limiting Toxicity</measure>
    <time_frame>48-50 week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>silymarin 420 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>420 mg Legalon (silymarin) three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>silymarin 700 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700 mg of Legalon (silymarin) three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (lactose pill)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>lactose pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin 700 mg</intervention_name>
    <description>700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
    <arm_group_label>silymarin 700 mg</arm_group_label>
    <other_name>Legalon</other_name>
    <other_name>milk thistle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin 420 mg</intervention_name>
    <description>420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
    <arm_group_label>silymarin 420 mg</arm_group_label>
    <other_name>Legalon</other_name>
    <other_name>milk thistle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years at screening.

          -  Informed consent signature.

          -  AST (aspartate aminotransferase) or ALT (alanine aminotransferase) greater than 40
             IU/L within one year of screening and at least once during the screening period.

          -  The participant must agree to adhere to the alcohol consumption guidelines.

          -  Have a liver biopsy performed within 12 months of randomization demonstrating features
             consistent with NASH without cirrhosis; NAS score of at least 4. Historical biopsy
             must include one Trichrome and one H&amp;E slide, otherwise the biopsy must be redone.

          -  No change in diabetic medications or insulin sensitizers (if applicable) between
             biopsy and screening or during the screening period.

          -  Weight loss/gain of no more than 10% between biopsy and screening, or within 30 days
             of screening if the biopsy is performed during the screening period.

          -  Negative urine pregnancy test (for women of childbearing potential) documented within
             the 24-hour period prior to the first dose of study medication. Females of
             childbearing potential must be using two reliable forms of effective contraception
             during the study (while on study drug and during follow-up).

        Exclusion Criteria:

          -  Use of silymarin or other milk thistle preparations for a period of 90 consecutive
             days or longer between biopsy and initial screening, or within 30 days prior to
             screening if the biopsy is performed during the screening period.

          -  Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol,
             or non-prescribed complementary alternative medications (including dietary
             supplements, megadose vitamins, herbal preparations, and special teas) within 30 days
             prior to screening. A multivitamin at standard doses will be allowed.

          -  Use of silymarin or other antioxidants or non-prescribed complementary alternative
             medications (as above) during the screening period or patient unwilling to refrain
             from taking these medications through completion of the study.

          -  BMI &gt; 45 kg/m2 between screening and randomization.

          -  Type 2 diabetes treated with oral agents other than the secretagogues or metformin;
             these include, thiazolidinediones, alpha-glucosidase inhibitors, exenatide,
             pramlintide between screening and randomization. Januvia (sitagliptin) is allowed.

          -  Evidence of poorly-controlled diabetes (defined as HbA1c &gt; 8% in patients with
             diabetes) between screening and randomization.

          -  Known allergy/sensitivity to milk thistle or its preparations.

          -  Use of drugs associated with a clinical or histological picture consistent with fatty
             liver disease or NASH for more than 12 consecutive weeks in the 1 year prior to
             screening; these include amiodarone, tamoxifen, methotrexate, glucocorticoids,
             anabolic steroids, tetracyclines, estrogens at doses greater than those used for
             hormone replacement, valproate/valproic acid.

          -  For patients using antihyperlipidemic agents or accepted anti-diabetic agents, any
             change of agent or dose from screening through randomization.

          -  Use of warfarin, metronidazole, or acetaminophen (greater than 2 grams per day) from
             screening through randomization.

          -  Lactose intolerance defined as patient reported inability to tolerate milk products.

          -  History of other chronic liver disease, including metabolic diseases, documented by
             appropriate test(s).

          -  Previous liver biopsy that demonstrated presence of cirrhosis.

          -  Radiologic imaging consistent with cirrhosis or portal hypertension.

          -  Clinical or histological evidence of cirrhosis or, in the opinion of the investigator,
             the inability to safely obtain a liver biopsy due to technical reasons, such as body
             habitus.

          -  Evidence of decompensated liver disease defined as any of the following: serum albumin
             &lt;3.2 g/dl, total bilirubin &gt; 1.5 mg/dl, or PT/INR (Prothrombin Time/International
             Normalized Ratio) &gt; 1.3 times normal at screening, or history or presence of ascites
             or encephalopathy, or bleeding from esophageal varices.

          -  Platelet count &lt; 130,000/mm3 at screening.

          -  Serum creatinine of 2.0 mg/dL or greater or CrCl ≤ 60cc/min, or on dialysis, at
             screening. The creatinine clearance (CrCl) will be calculated according to
             Cockcroft-Gault.

          -  Average alcohol consumption of more than one drink or equivalent (&gt;12 grams) per day
             or more than two (2) drinks on any one day over the 30 days prior to screening.
             Patients who met either criterion more than 30 days prior to screening must have
             consumed a monthly average of 12 grams or less per day of alcohol for at least six
             months prior to screening.

          -  Evidence of drug abuse in the year prior to screening or prior to randomization.

          -  History of immunologically mediated disease (e.g., inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia,
             severe psoriasis, rheumatoid arthritis) that could affect the assessment of biomarkers
             of inflammation.

          -  History of solid organ or bone marrow transplantation.

          -  History of thyroid disease poorly controlled on prescribed medications.

          -  Use of oral steroids for more than 14 days within 30 days of screening or prior to
             randomization.

          -  Primary hepatic malignancy.

          -  Secondary hepatic malignancy (metastatic disease) or extrahepatic malignancy.

          -  Women with ongoing pregnancy or breast feeding, or contemplating pregnancy.

          -  History of bariatric surgery, or undergoing evaluation for bariatric surgery.

          -  Participation in a research drug trial, exclusive of the SyNCH Phase I trial, within
             30 days of screening.

          -  History or other evidence of severe illness or any other conditions that would make
             the patient, in the opinion of the investigator, unsuitable for the study (such as
             poorly controlled psychiatric disease, coronary artery disease, or active
             gastrointestinal conditions that might interfere with drug absorption).

          -  Inability or unwillingness to give informed consent or abide by the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victor Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nezam Afdhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K. Rajender Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven H. Belle, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen A. Harrison, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Isreal Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>December 23, 2015</results_first_submitted>
  <results_first_submitted_qc>December 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2016</results_first_posted>
  <last_update_submitted>December 23, 2015</last_update_submitted>
  <last_update_submitted_qc>December 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited at 5 sites; first observation April 30, 2008, last observation Nov 12, 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Silymarin 420 mg</title>
          <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="P2">
          <title>Silymarin 700 mg</title>
          <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Silymarin 420 mg</title>
          <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="B2">
          <title>Silymarin 700 mg</title>
          <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.3" spread="10.83"/>
                    <measurement group_id="B2" value="48.2" spread="11.43"/>
                    <measurement group_id="B3" value="49.51" spread="10.89"/>
                    <measurement group_id="B4" value="48.3" spread="10.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy - Improvement by at Least 2 Points in Histology (NAS)</title>
        <time_frame>48-50 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silymarin 420 mg</title>
            <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Silymarin 700 mg</title>
            <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Improvement by at Least 2 Points in Histology (NAS)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Occurrence of a Dose-limiting Toxicity</title>
        <time_frame>48-50 week treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Silymarin 420 mg</title>
            <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Silymarin 700 mg</title>
            <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Occurrence of a Dose-limiting Toxicity</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Efficacy - Improvement by at Least 2 Points in Histology (NAS) - With NAS Without Cirrhosis</title>
        <description>This outcome measure excludes the substantial percentage (62.8%) of patients with baseline biopsies that were deemed ineligible (per inclusion criteria) by the central pathologist due to NAS &lt;4 or absence of NASH (nonalcoholic steatohepatitis) (n=34), NASH with presence of cirrhosis (n=1), or slides unavailable/not evaluable for reading (n=14).</description>
        <time_frame>48-50 week treatment period</time_frame>
        <population>Subgroup of ITT (Intent to Treat) Patients with NASH and without cirrhosis population</population>
        <group_list>
          <group group_id="O1">
            <title>Silymarin 420 mg</title>
            <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O2">
            <title>Silymarin 700 mg</title>
            <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy - Improvement by at Least 2 Points in Histology (NAS) - With NAS Without Cirrhosis</title>
          <description>This outcome measure excludes the substantial percentage (62.8%) of patients with baseline biopsies that were deemed ineligible (per inclusion criteria) by the central pathologist due to NAS &lt;4 or absence of NASH (nonalcoholic steatohepatitis) (n=34), NASH with presence of cirrhosis (n=1), or slides unavailable/not evaluable for reading (n=14).</description>
          <population>Subgroup of ITT (Intent to Treat) Patients with NASH and without cirrhosis population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Silymarin 420 mg</title>
          <description>420 mg Legalon (silymarin) three times daily
Silymarin 420 mg: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="E2">
          <title>Silymarin 700 mg</title>
          <description>700 mg of Legalon (silymarin) three times daily
Silymarin 700 mg: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo (lactose pill)
Placebo: Placebo (5 pills, three times daily) for 48-50 week treatment period</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LOW PLATELET COUNT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE HEMATOMA POST TREATMENT LIVER BIOPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK SURGERY L5/S1</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HOSPITALIZED FOR SEVERE HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gasto-intestinal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urological</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatologic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Research and Operations</name_or_title>
      <organization>Meda Pharmaceuticals, Inc.</organization>
      <email>michael.purzycki@meda.us</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

